The LADERA trial found that while dose interruptions were slightly higher with the oral SERD gerodestrant, treatment discontinuations were lower compared to standard of care. Specifically, fewer patients stopped treatment due to musculoskeletal symptoms, suggesting a clinically meaningful advantage in patient adherence.
Despite the promise of liquid biopsies for monitoring, the SERENA-6 trial revealed a significant challenge: fewer than 10% of screened patients developed a detectable ESR1 mutation. This low yield questions the efficiency and broad applicability of this serial screening strategy to guide treatment changes.
In the EMBER-3 trial, the combination of the oral SERD imlunestrant and the CDK4/6 inhibitor abemaciclib showed a 41% reduction in progression risk versus the SERD alone. Critically, this benefit was observed regardless of the patient's ESR1 mutation status, indicating a broader mechanism of action.
Fulvestrant's activity against ESR1-mutated cancer is weaker than expected. This is likely due to its intramuscular delivery, which may limit the drug concentration needed to overcome the constitutively active estrogen receptor. This pharmacokinetic failure helped drive the development of more bioavailable oral SERDs.
Circulating tumor DNA (ctDNA) assays show high concordance with tissue biopsies and may yield a higher rate of identifying ESR1 mutations. This is because ctDNA captures tumor heterogeneity from multiple metastatic sites, which a single tissue sample can miss, providing a more comprehensive genomic picture.
Comparing elacestrant (EMERALD) and imlunestrant (EMBER-3) is flawed because the patient populations were fundamentally different. EMERALD's patients were more heavily pretreated, a fact starkly illustrated by the standard-of-care arms' median Progression-Free Survival of 1.9 months versus 3.8 months in EMBER-3.